LIGAND PHARMACEUTICALS (LGND) Fundamental Analysis & Valuation

NASDAQ:LGND • US53220K5048

201.9 USD
-4.37 (-2.12%)
At close: Mar 6, 2026
201.9 USD
0 (0%)
After Hours: 3/6/2026, 4:30:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This LGND fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, LGND scores 5 out of 10 in our fundamental rating. LGND was compared to 193 industry peers in the Pharmaceuticals industry. While LGND belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. LGND has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

7

1. LGND Profitability Analysis

1.1 Basic Checks

  • LGND had positive earnings in the past year.
  • In the past year LGND had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: LGND reported negative net income in multiple years.
  • LGND had a positive operating cash flow in 4 of the past 5 years.
LGND Yearly Net Income VS EBIT VS OCF VS FCFLGND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

  • The Return On Assets of LGND (3.29%) is better than 83.42% of its industry peers.
  • LGND has a better Return On Equity (5.11%) than 83.94% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 1.58%, LGND is in the better half of the industry, outperforming 79.27% of the companies in the same industry.
  • LGND had an Average Return On Invested Capital over the past 3 years of 1.12%. This is significantly below the industry average of 13.00%.
  • The 3 year average ROIC (1.12%) for LGND is below the current ROIC(1.58%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.29%
ROE 5.11%
ROIC 1.58%
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
LGND Yearly ROA, ROE, ROICLGND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

1.3 Margins

  • Looking at the Profit Margin, with a value of 19.34%, LGND belongs to the top of the industry, outperforming 91.71% of the companies in the same industry.
  • LGND has a Operating Margin of 11.48%. This is amongst the best in the industry. LGND outperforms 84.97% of its industry peers.
  • In the last couple of years the Operating Margin of LGND has declined.
  • Looking at the Gross Margin, with a value of 94.27%, LGND belongs to the top of the industry, outperforming 96.37% of the companies in the same industry.
  • In the last couple of years the Gross Margin of LGND has remained more or less at the same level.
Industry RankSector Rank
OM 11.48%
PM (TTM) 19.34%
GM 94.27%
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
LGND Yearly Profit, Operating, Gross MarginsLGND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300 400 500

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. LGND Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so LGND is destroying value.
  • LGND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LGND Yearly Shares OutstandingLGND Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
LGND Yearly Total Debt VS Total AssetsLGND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

  • LGND has an Altman-Z score of 6.06. This indicates that LGND is financially healthy and has little risk of bankruptcy at the moment.
  • LGND's Altman-Z score of 6.06 is fine compared to the rest of the industry. LGND outperforms 78.24% of its industry peers.
  • The Debt to FCF ratio of LGND is 14.48, which is on the high side as it means it would take LGND, 14.48 years of fcf income to pay off all of its debts.
  • LGND has a Debt to FCF ratio of 14.48. This is in the better half of the industry: LGND outperforms 78.24% of its industry peers.
  • LGND has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
  • LGND's Debt to Equity ratio of 0.47 is on the low side compared to the rest of the industry. LGND is outperformed by 60.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 14.48
Altman-Z 6.06
ROIC/WACC0.17
WACC9.33%
LGND Yearly LT Debt VS Equity VS FCFLGND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

  • LGND has a Current Ratio of 24.69. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
  • LGND has a Current ratio of 24.69. This is amongst the best in the industry. LGND outperforms 93.26% of its industry peers.
  • A Quick Ratio of 24.30 indicates that LGND has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 24.30, LGND belongs to the best of the industry, outperforming 92.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 24.69
Quick Ratio 24.3
LGND Yearly Current Assets VS Current LiabilitesLGND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. LGND Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.81% over the past year.
  • Measured over the past years, LGND shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.06% on average per year.
EPS 1Y (TTM)40.81%
EPS 3Y23.39%
EPS 5Y12.06%
EPS Q2Q%59.06%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%39.37%

3.2 Future

  • Based on estimates for the next years, LGND will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.98% on average per year.
  • The Revenue is expected to grow by 13.58% on average over the next years. This is quite good.
EPS Next Y5.61%
EPS Next 2Y10.48%
EPS Next 3Y9.34%
EPS Next 5Y12.98%
Revenue Next Year9.39%
Revenue Next 2Y14.11%
Revenue Next 3Y13.08%
Revenue Next 5Y13.58%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
LGND Yearly Revenue VS EstimatesLGND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
LGND Yearly EPS VS EstimatesLGND Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

4

4. LGND Valuation Analysis

4.1 Price/Earnings Ratio

  • LGND is valuated quite expensively with a Price/Earnings ratio of 25.11.
  • Compared to the rest of the industry, the Price/Earnings ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 79.27% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.29. LGND is around the same levels.
  • With a Price/Forward Earnings ratio of 23.78, LGND is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 75.65% of the companies listed in the same industry.
  • LGND is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 24.57, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 25.11
Fwd PE 23.78
LGND Price Earnings VS Forward Price EarningsLGND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, LGND is valued a bit cheaper than 77.20% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 76.17% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 130.88
EV/EBITDA 53.44
LGND Per share dataLGND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates LGND does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of LGND may justify a higher PE ratio.
PEG (NY)4.47
PEG (5Y)2.08
EPS Next 2Y10.48%
EPS Next 3Y9.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LGND Dividend Analysis

5.1 Amount

  • LGND does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LGND Fundamentals: All Metrics, Ratios and Statistics

LIGAND PHARMACEUTICALS

NASDAQ:LGND (3/6/2026, 4:30:03 PM)

After market: 201.9 0 (0%)

201.9

-4.37 (-2.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners106.73%
Inst Owner Change-42.5%
Ins Owners1.62%
Ins Owner Change1.93%
Market Cap4.03B
Revenue(TTM)N/A
Net Income(TTM)48.58M
Analysts85.71
Price Target248.31 (22.99%)
Short Float %7.06%
Short Ratio6.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.83%
Min EPS beat(2)10.36%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)19.98%
Min EPS beat(4)4.63%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)37.45%
EPS beat(12)12
Avg EPS beat(12)53.58%
EPS beat(16)15
Avg EPS beat(16)61.91%
Revenue beat(2)2
Avg Revenue beat(2)25.66%
Min Revenue beat(2)6.44%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)18.43%
Min Revenue beat(4)6.44%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.31%
Revenue beat(12)11
Avg Revenue beat(12)12.65%
Revenue beat(16)14
Avg Revenue beat(16)16.25%
PT rev (1m)0%
PT rev (3m)6.72%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.6%
EPS NY rev (1m)0%
EPS NY rev (3m)10.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.73%
Valuation
Industry RankSector Rank
PE 25.11
Fwd PE 23.78
P/S 16.02
P/FCF 130.88
P/OCF 126.14
P/B 4.24
P/tB 9.85
EV/EBITDA 53.44
EPS(TTM)8.04
EY3.98%
EPS(NY)8.49
Fwd EY4.21%
FCF(TTM)1.54
FCFY0.76%
OCF(TTM)1.6
OCFY0.79%
SpS12.6
BVpS47.65
TBVpS20.5
PEG (NY)4.47
PEG (5Y)2.08
Graham Number92.84
Profitability
Industry RankSector Rank
ROA 3.29%
ROE 5.11%
ROCE 1.99%
ROIC 1.58%
ROICexc 2.92%
ROICexgc 9.48%
OM 11.48%
PM (TTM) 19.34%
GM 94.27%
FCFM 12.24%
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
ROICexc(3y)1.91%
ROICexc(5y)2.67%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.87%
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 14.48
Debt/EBITDA 7.07
Cap/Depr 3.38%
Cap/Sales 0.46%
Interest Coverage 96.15
Cash Conversion 50.63%
Profit Quality 63.32%
Current Ratio 24.69
Quick Ratio 24.3
Altman-Z 6.06
F-Score5
WACC9.33%
ROIC/WACC0.17
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.81%
EPS 3Y23.39%
EPS 5Y12.06%
EPS Q2Q%59.06%
EPS Next Y5.61%
EPS Next 2Y10.48%
EPS Next 3Y9.34%
EPS Next 5Y12.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%39.37%
Revenue Next Year9.39%
Revenue Next 2Y14.11%
Revenue Next 3Y13.08%
Revenue Next 5Y13.58%
EBIT growth 1Y64.02%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year674.52%
EBIT Next 3Y155.76%
EBIT Next 5Y79.51%
FCF growth 1Y-61.26%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-66.41%
OCF growth 3Y7.19%
OCF growth 5YN/A

LIGAND PHARMACEUTICALS / LGND FAQ

What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?

ChartMill assigns a fundamental rating of 5 / 10 to LGND.


What is the valuation status of LIGAND PHARMACEUTICALS (LGND) stock?

ChartMill assigns a valuation rating of 4 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.


How profitable is LIGAND PHARMACEUTICALS (LGND) stock?

LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 7 / 10.


What is the financial health of LIGAND PHARMACEUTICALS (LGND) stock?

The financial health rating of LIGAND PHARMACEUTICALS (LGND) is 6 / 10.